EMICIZUMAB and HEAD INJURY

Overview

HEAD INJURY is the #9 most commonly reported adverse reaction for EMICIZUMAB, manufactured by Genentech, Inc.. There are 313 FDA adverse event reports linking EMICIZUMAB to HEAD INJURY. This represents approximately 2.1% of all 15,224 adverse event reports for this drug.

Patients taking EMICIZUMAB who experience head injury should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.

Reporting Frequency

HEAD INJURY is a less commonly reported adverse event for EMICIZUMAB, but still significant enough to appear in the safety profile.

Other Side Effects of EMICIZUMAB

In addition to head injury, the following adverse reactions have been reported for EMICIZUMAB:

• HAEMORRHAGE — 4,059 reports
• NO ADVERSE EVENT — 754 reports
• HAEMARTHROSIS — 739 reports
• OFF LABEL USE — 725 reports
• FALL — 587 reports
• ARTHRALGIA — 462 reports
• CONTUSION — 369 reports
• EPISTAXIS — 358 reports
• PAIN — 301 reports
• MUSCLE HAEMORRHAGE — 282 reports

Does EMICIZUMAB cause HEAD INJURY?

HEAD INJURY has been reported as an adverse event in 313 FDA reports for EMICIZUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.

How common is HEAD INJURY with EMICIZUMAB?

HEAD INJURY accounts for approximately 2.1% of all adverse event reports for EMICIZUMAB, making it a notable side effect.

What should I do if I experience HEAD INJURY while taking EMICIZUMAB?

If you experience head injury while taking EMICIZUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.

Related Pages